What is claimed is:

1. Use of a~~A~~ complement inhibitor ~~for use in~~: the manufacture of a medicament for (i) treating a patient afflicted with Degos' disease or (ii) lessening the severity of one or more symptoms of Degos' disease in a patient, wherein the Degos' disease is multiorgan, systemic Degos' disease.

2. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is to be chronically administered to the patient.

3. The ~~complement inhibitor for~~ use according to claim 1, wherein the Degos' disease is associated with a B19 parvoviral infection or human immunodeficiency virus infection.

4. The ~~complement inhibitor for~~ use according to claim 1, wherein the Degos' disease is idiopathic.

5. The ~~complement inhibitor for~~ use according to claim 1, wherein the Degos' disease pathologically affects the gastrointestinal tract, the central nervous system, or the cardiovascular system.

6. The ~~complement inhibitor for~~ use according to claim 1, wherein the Degos' disease is refractory to at least one therapy selected from the group consisting of an anti-inflammatory agent, an anticoagulant, an antithrombotic, and intravenous immunoglobulin.

7. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is selected from the group consisting of soluble CR1, LEX-CR1, MCP, DAF, CD59, Factor H, cobra venom factor, FUT-175, complestatin, and K76 COOH.

8. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is an antibody or an antigen-binding fragment thereof that binds to a human complement component protein.

9. The ~~complement inhibitor for~~ use according to claim 8, wherein the antibody or antigen-binding antigen-binding fragment thereof binds to a human complement component CS protein.

10. The ~~complement inhibitor for~~ use according to claim 8, wherein the antibody or antigen-binding fragment thereof inhibits the cleavage of complement component C5 into fragments C5a and C5b.

~~.~~11. The ~~complement inhibitor for~~ use according to claim 8, wherein the antibody or antigen- binding antigen-binding fragment thereof is selected from the group consisting of a humanized antibody, a recombinant antibody, a diabody, a chimerized or chimeric antibody, a deimmunized human antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab' fragment, and an $F(ab')_2$ fragment.

12. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is eculizumab.

13. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is pexelizumab.

14. The ~~complement inhibitor for~~ use according to claim 1, wherein the complement inhibitor is to be administered to the patient in conjunction with an inhibitor of interferon alpha.

15. A pharmaceutical composition or package comprising: ~~the~~ a complement inhibitor ~~of claim~~ 1 for use in (i) treating a patient afflicted with Degos' disease or (ii) lessening the severity of one or more symptoms of Degos' disease in a patient, wherein the Degos' disease is multiorgan, systemic Degos' disease.

~~16. Use of a complement inhibitor as claimed in any one of claims 1 to 14, in the manufacture of a medicament for (i) treating a patient affected with Degos' disease or (ii) lessening the severity of one or more symptoms of Degos' disease in a patient, wherein the Degos' disease is multiorgan, systemic Degos' disease.~~